Merck’s HS Data Validates the TL1A Pathway — and Helps Shattuck Labs
Merck’s tulisokibart met its Phase 2b HS goal and will move to Phase 3. H.C. Wainwright sees first anti-TL1A skin data as a class plus for Shattuck.
/ 3 items
#STTK↓
Shattuck Labs Stock Gets Bullish Citi Upgrade Before SL-325 Phase 1 Results
Citi upgrades STTK to Buy with $7 price target and 30-day upside watch ahead of SL-325 Phase 1 data in Q2 2026.
Piper Sandler Starts Coverage on Shattuck Labs with Bullish View
Piper Sandler begins coverage of Shattuck Labs with an Overweight rating and $15 target, highlighting promise of SL-325 ahead of Phase 1 data.